Moderna Inc

NASDAQ:MRNA  
127.28
+18.10 (+16.58%)
Other Pre-Announcement

Moderna Has Completed Case Accrual For First Planned Interim Analysis Of Its Vaccine Against Covid-19

Published: 11/11/2020 21:42 GMT
Moderna Inc (MRNA) - Moderna Has Completed Case Accrual for First Planned Interim Analysis of Its Mrna Vaccine Against Covid-19 (mrna-1273).
Moderna Inc - Expects More Than 53 Cases Will Be Submitted to Data Safety Monitoring Board for First Interim Analysis.
Moderna Inc - Acceleration in Rate of Covid-19 Disease Across Trial Sites.
Moderna Inc - Expects More Than 53 Cases Will Be Submitted to Data Safety Monitoring Board for First Interim Analysis.
Moderna Inc - Seen a Significant Increase in Rate of Case Identification Across Sites in Last Week.
Moderna Inc - Data on More Than 53 Cases is Being Prepared for Submission to Independent Data Safety Monitoring Board for Analysis and Recommendation.
Moderna Inc - Remains Blinded to Whether Participants on Cove Study Received Vaccine Or Placebo.
Moderna Inc - Expects to Be Able to Produce About 20 Million Doses of Mrna-1273 in 2020 and From 500 Million Up to One Billion Doses Worldwide in 2021.